Tagged: VRX

Valeant VRX 0

Valeant Pharmaceuticals Intl Inc (VRX) Approved as Stalking Horse Bidder for Dendreon Assets

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has entered an amended and restated stalking horse bid to acquire certain assets of Dendreon Corporation including the world-wide rights to Dendreon’s PROVENGE product. In response to competing bids,...

allergan 0

Allergan, Inc. (AGN) 4Q Results to Benefit From Range Of Products And Cost Reduction Initiatives

Allergan, Inc. (NYSE:AGN)’s strength has always been in it’s range of products. This is one of the reasons why companies like Valeant Pharmaceuticals Intl Inc (NYSE:VRX) indulged in an unsolicited attempt to buy Allergan, Inc. (NYSE:AGN). Allergan...

BauschLomb 0

Valeant Pharmaceuticals Intl Inc (VRX): Bausch + Lomb Imaging System Receives U.S. FDA Clearance

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s wholly owned subsidiary Bausch + Lomb recently secured U.S. FDA clearance for an advanced Swept Source OCT and updated software for its VICTUS® Femtosecond Laser Platform. VICTUS is one of the...

0

Valeant Pharmaceuticals Intl Inc (VRX) announces redemption of $445.0 Million of 6.875% Senior Notes Due 2018

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) announced the redemption of $445.0 Million of 6.875% Senior Notes Due in 2018.  After the transaction, the company will have approximately $500.0 million outstanding of the 6.875% Senior...

Valeant VRX 0

A look at Valeant Pharmaceuticals

Valeant Pharmaceuticals International (VRX) Commentary on five year developments in the balance sheet, sales, cash flow, per share earnings trends. Valeant is a multinational specialty pharmaceutical and medical device company. CEO J. Michael Pearson...